Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03063827
Other study ID # BuddhistTCGH 098-53
Secondary ID
Status Completed
Phase N/A
First received February 21, 2017
Last updated March 9, 2017
Start date January 2010
Est. completion date December 2012

Study information

Verified date March 2017
Source Buddhist Tzu Chi General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study investigated the changes in urothelial dysfunction and sensory protein expression in the bladder urothelium with time after onabotulinumtoxin injection in spinal cord injured (SCI) patients. The investigators planned to enroll 30 chronic SCI patient with neurogenic detrusor overactivity and urinary incontinence were treated with a single injection of 200 U onabotulinumtoxinA at the detrusor. Video urodynamic studies and bladder mucosal biopsies were performed at baseline, 3 months, and 6 months after treatment. Bladder tissues will be investigated for urothelial barrier and inflammation proteins as well as sensory proteins by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups. This study will explore the therapeutic efficacy of a single injection of 200 U onabotulinumtoxinA on neurogenic detrusor overactivity and the changes of urothelial sensory proteins in SCI patients with successful and failed treatment outcome.


Description:

In recent decades, treatment of neurogenic detrusor overactivity (NDO) with onabotulinumtoxinA has emerged as an alternative method for the management of urological complications due to spinal cord injury (SCI) or multiple sclerosis. Injection of 200-300 U of onabotulinumtoxinA into the detrusor muscle can reduce contractility, improve bladder compliance, and restore urinary continence in patients with NDO. However, detrusor underactivity will develop after injection of 300 U of onabotulinumtoxinA and improvement of urodynamic and quality of life parameters lasted 9 months. Currently, a 200 U single injection of onabotulinumtoxinA into the detrusor has been recommended as standard treatment for NDO. However, the therapeutic duration of this dosage on NDO was shorter than that of a 300 U injection.

OnabotulinumtoxinA effectively improves lower urinary tract symptoms by inhibiting signal transmission at the neuromuscular and neuroglandular junctions. OnabotulinumtoxinA cleaves synaptosome-associated protein 25 and inhibits signal transmission by disrupting fusion of neurotransmitter- containing vesicles with the neuronal wall. In the urinary bladder, release of acetylcholine from both pre- and postganglionic parasympathetic nerves is blocked after onabotulinumtoxinA administration. This toxin was also found to modulate afferent activity of the bladder associated with reduced urgency and urgency urinary incontinence symptoms in NDO patients. Although the impact of onabotulinumtoxinA on the sympathetic nervous system within the urinary bladder is unclear, it has an inhibitory effect on release of norepinephrine to α- and β3-adrenoreceptors (β3-ARs) which regulate bladder neck contraction and detrusor relaxation, respectively.

A previous study reported decreased expression of adhesion and junction proteins E-cadherin and zonula occludens-1 (ZO-1), respectively, and increased suburothelial inflammation with apoptosis in patients with chronic SCI bladders.The urothelial inflammation and dysfunction in SCI bladders might also alter sensory protein expression, such as in purinergic receptor P2X3, transient receptor potential vallinoid receptor subfamily 1, adenosine triphosphate, and nitric oxide. Urothelial dysfunction might also result in increased excitability of the C-fibers which become predominantly afferent nerves of the micturition reflex after SCI. In humans with NDO, the levels of bladder P2X2, P2X3, and muscarinic receptors M2 and M3 were reduced after detrusor onabotulinumtoxinA injection, suggesting this toxin inhibits DO by inhibiting both the sensory and motor arms of the micturition reflex. In addition, β3-ARs are known to promote urine storage in the bladder by inducing detrusor relaxation in animal and human bladders. In humans, β3-AR is the predominant β-receptor subtype in the urinary bladder. There has been no report on β3-AR changes in SCI bladder urothelium before or after onabotulinumtoxin treatment.

After onabotulinumtoxinA injection, patients may be symptom-free for a period of 3-6 months before symptoms relapse. Most studies of onabotulinumtoxinA on NDO come from animal models, and only a few human studies have been noted. The current study investigated changes in urothelial dysfunction and sensory protein expression in the bladder urothelium with time after a single onabotulinumtoxin injection in SCI patients.

Materials and Methods

A total of 26 patients with chronic SCI causing NDO and urinary incontinence were treated with a single injection of 200 U onabotulinumtoxinA to the detrusor muscle. All patients presented with urinary incontinence with or without difficult bladder emptying. In patients who received detrusor injections, clean intermittent catheterization was suggested as a possible mode of urinary management after treatment. The current study was approved by the Institutional Review Board and Ethics Committee of Buddhist Tzu Chi General Hospital (IRB:098-53). Each patient was informed about the study rationale and procedures, and written informed consent to participate was obtained before any bladder procedure.

Video urodynamic studies

All patients received a video urodynamic study (VUDS) before their enrollment. Bladder and urethral dysfunction were classified as the presence of DO with coordinated or dyssynergic urethral sphincter activity. Patients with urinary tract infection were properly treated before they were scheduled for onabotulinumtoxinA injection. VUDS results were interpreted according to the recommendations of the International Continence Society. VUDS parameters included maximum flow rate (Qmax), detrusor voiding pressure at Qmax (Pdet), cystometric bladder capacity (CBC), voided volume (Vol), and post-void residual (PVR) volume.

OnabotulinumtoxinA injection

All patients received 200 U of onabotulinumtoxinA in 20 mL normal saline (BOTOX®, 100 U/vial, Allergan Inc., Irvine, USA) in the operation room by rigid cytoscopic injection (22 Fr, Richard Wolf, Knittlingen, Germany) into 40 sites of the bladder wall, sparing the trigoneAfter injection, a urethral Foley catheter was routinely inserted and removed the next morning before patients were discharged. Broad spectrum antibiotics were prescribed for 3 d after treatment.

After onabotulinumtoxinA injection, four bladder cold-cup biopsies were taken randomly at the posterior wall about 2 cm above the interureteric ridge, and only the bladder mucosa and submucosa were taken to prevent bladder perforation; any erythematous or inflammatory bladder mucosa were avoided. One bladder biopsy specimen from each patient was sent to the pathology department to exclude the possibility of carcinoma in situ. The remaining three specimens from each patient were stored at optimum cutting temperature and in liquid nitrogen for further immunohistochemistry studies.

Patient follow-up and outcome assessment

Patients were followed up at OPD monthly, and VUDS and assessment of bladder and voiding conditions and satisfaction with treatment were performed 3 and 6 months after treatment. If the CBC increased by 50% from the baseline value, the treatment outcome was considered successful; otherwise, the outcome was considered a failure at that time-point. Ten female patients with stress-related urinary incontinence without frequent urgency served as controls. All control patients were confirmed free of bladder outlet obstruction or DO by VUDS. Control bladder tissue was obtained during anti-incontinence surgery and processed the same as SCI patients. Male patients were not selected to serve as controls because the prostate could cause bladder outlet obstruction and affect urothelial function.

Immunofluorescence

Bladder tissue samples from SCI patients and controls were examined for changes in urothelial E-cadherin (adhesive protein), ZO-1 (junction protein), and mast cell activation (tryptase) levels by immunofluorescence; cellular apoptosis was examined by terminal deoxynucleotidyl transferase dUTP nick end-labeling assay. These procedures were performed similar to those in our previous study, with 6-μm thickness tissue sections. Urinary bladder specimens were immersed and fixed for 1 h in ice-cold 4% formaldehyde in phosphate-buffered saline (pH 7.4) then rinsed with ice-cold phosphate-buffered saline containing 15% sucrose for 12 h. Biopsy specimens were embedded in optimum cutting temperature medium and stored at −80 °C. Four sections per specimen were cut using a cryostat at a thickness of 8 μm and collected on new silane III-coated glass slides (Muto Pure Chemicals Co., Ltd, Tokyo, Japan). Sections were postfixed in acetone at −20 °C and blocked with rabbit serum. The sections were incubated overnight at 4 °C with antihuman E-cadherin (BD Biosciences, San Jose, CA, USA) or tryptase (Chemicon, Temecula, CA, USA) primary antibodies. After rinsing the sections with 0.1% Tween-20 in BPS, rabbit antimouse-conjugated fluorescein isothiocyanate secondary antibodies (DakoCytomation Denmark A/S, Glostrup, Denmark) were applied and incubated on sections for 1 h. Finally, sections were counterstained with 4',6-diamidino-2-phenylindole (Sigma Chemical Co., St. Louis, MO, USA). Negative controls included the isotype of the primary antibody. We obtained the mean, maximum, range, and standard deviation of the staining intensity and percent positive area measurements using three random hot spots within each specimen.

Immunofluorescence quantification was determined in four consecutive high-power fields (400X) in the area with the greatest density. Immunofluorescence (tryptase and terminal deoxynucleotidyl transferase dUTP nick end-labeling) assays were quantified by counting the number of positively stained cells per unit area (4 μm2) and are shown as percentages. The intensity of E-cadherin (fluorescence microscopy) and ZO-1 (confocal microscopy) fluorescence was quantified using Image J.

Western blotting was used to assess the levels of sensory proteins in bladder mucosa specimens. Primary antibodies included P2X3 (1:2000), endothelial nitric oxide synthase [eNOS] (1:1000), M2 (1:1000), M3 (1:500), and GAPDH (1:100000; internal control) from GeneTex (Irvine, CA, USA); inducible NOS [iNOS] (1:1500; ThermoFisher, Rockford, IL, USA); and β3-AR (1:1000; Abcam, Cambridge, UK). Donkey antigoat (for β3-AR) or goat antirabbit (for all other proteins) IgG-horseradish peroxidase (1:3000; Santa Cruz Biotechnology, Dallas, TX, USA) secondary antibodies were used. The scanned film after gel electrophoresis was quantified using a gel documentation system (Quantity One Version 4.6.2, Bio-Rad Laboratories, Hemel Hempstead, Herts, UK). Procedures were similar to those described in our previous study.

Statistical Analysis

Continuous variables were presented as means ± standard deviations, and categorical data were presented as numbers and percentages. Eligible SCI patients were grouped according to treatment outcome and compared with controls. Differences in the levels of functional proteins in the urothelium at baseline and 3 and 6 months after onabotulinumtoxinA injection were analyzed using a paired Student's t-test. Differences in immunofluorescence and Western blot of sensory proteins between successful and failed treatment groups were analyzed using the Kruskal-Wallis test. In order to clarify the roles of urothelial sensory proteins in NDO, correlation analysis using linear regression was also performed, including VUDS and urothelial dysfunction parameters. All calculations were done using SPSS for Windows version 16.0 (SPSS, Chicago, IL, USA). Differences were considered statistically significant if P values were less than 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients with chronic SCI causing NDO and urinary incontinence

Exclusion Criteria:

- patients did not present with urinary incontinence

- patients are known to be allergic to onabotulinumtoxinA

- patients cannot be followed up regularly

- active urinary tract infection

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
OnabotulinumtoxinA 200 UNT
Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
Diagnostic Test:
Urothelial sensory protein levels
Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Buddhist Tzu Chi General Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Bladder capacity The maximal cystometric or functional bladder capacity from baseline to 6 months after treatment
Secondary IIQ-7 Incontinence impact questionnare score from baseline to 6 months after treatment
Secondary UDI-6 Urogenital distress inventory score from baseline to 6 months after treatment
Secondary Sensory protein assessment The changes of urothelial sensory protein levels from baseline to 6 months after treatment
See also
  Status Clinical Trial Phase
Recruiting NCT02978638 - Electrical Stimulation for Continence After Spinal Cord Injury N/A
Enrolling by invitation NCT06429631 - The Effect of CIC Education on QOL and Compliance With Mobile Application in Individuals With Spinal Cord Injury. N/A
Completed NCT03573726 - Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life N/A
Recruiting NCT06059066 - Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction N/A
Completed NCT01429090 - Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution Phase 1
Recruiting NCT05587101 - Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis
Terminated NCT03843073 - Connected Catheter- Safety and Effectiveness Study N/A
Terminated NCT04059159 - Connected Catheter - Safety and Effectiveness Study N/A
Completed NCT05858840 - Urinary Artificial Sphincter in Children
Completed NCT05861024 - Urinary Calculi After Bladder Augmentation in Children
Completed NCT04074616 - Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation N/A
Completed NCT05683938 - GentleCath™ Air Intermittent Catheter Smartwatch Real Life Pilot Study
Completed NCT04543552 - A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
Active, not recruiting NCT06247033 - Efficacies of Different Managements in Patients With Overactive Bladder With Stroke N/A
Withdrawn NCT01305681 - Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization Phase 1/Phase 2
Recruiting NCT04248322 - Qualitative Assessment of the Impact of TTNS on QOL and Participation
Recruiting NCT05301335 - Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study N/A
Recruiting NCT04924569 - Continence Care Registry
Completed NCT01716624 - Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Phase 3
Completed NCT01297647 - Incidence of Urinary Tract Infection After Urodynamic Investigation N/A